Codonopsis lanceolata oligopeptide composition with effects of enriching blood and tonifying qi as well as preparation method and application of codonopsis lanceolata oligopeptide composition

Abstract

The invention discloses a codonopsis lanceolata oligopeptide composition with effects of enriching blood and tonifying qi as well as a preparation method and application of the codonopsis lanceolata oligopeptide composition. The codonopsis lanceolata oligopeptide composition is prepared from the following components in parts by weight: 2 to 5 parts of codonopsis lanceolata oligopeptide, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of fructus lycii extract, 1 to 2 parts of roselle powder and 0.2 to 0.5 part of fish maw oligopeptide. And 0.5 to 1 part of a compound nutrition enhancer. The codonopsis lanceolata oligopeptide composition in one embodiment of the invention can improve exhaustive swimming time of mice with qi-deficiency constitution, increase spleen index, increase the number of blood cells in blood of the mice with blood deficiency and increase secretion of hematopoietic factors to promote hematopoietic function and improve immunity of the organism, thereby improving diseases of blood deficiency and qi deficiency.

Description

Technical Field

[0001] This application relates to the field of functional food technology, specifically to a blood-tonifying and qi-tonifying oligopeptide composition of Codonopsis pilosula, its preparation method, and its uses. Background Art

[0002] In Traditional Chinese Medicine (TCM) theory, Qi deficiency and blood deficiency are two closely related and clinically common syndromes. Qi deficiency is mainly manifested as weakness, fatigue, shortness of breath, reluctance to speak, spontaneous sweating, pale complexion, pale tongue, and weak pulse. Blood deficiency is mainly manifested as sallow or pale complexion, pale lips and nails, dizziness, palpitations, insomnia, numbness in the limbs, pale tongue, and weak pulse. Qi deficiency is often caused by prolonged illness, overwork, insufficient diet, or weak congenital constitution, involving dysfunction of the lungs, spleen, and heart. Blood deficiency is mostly caused by excessive blood loss, weak spleen and stomach leading to insufficient blood production, and prolonged illness depleting Yin and blood. Qi and blood are interdependent and mutually generative; "Qi is the commander of blood, and blood is the mother of Qi." Qi deficiency can lead to insufficient blood production, resulting in secondary blood deficiency, while blood deficiency can also aggravate Qi deficiency, forming a complex state of both Qi and blood deficiency. Qi and blood deficiency not only seriously affects the patient's quality of life, but also often leads to a variety of complications such as low immunity, chronic fatigue syndrome, and anemia.

[0003] Currently, clinical treatment for qi and blood deficiency often uses traditional Chinese medicine (such as ginseng and astragalus) or Western medicine (such as energy supplements and iron supplements), but these methods have the following limitations:

[0004] Traditional Chinese medicine compound prescriptions: The decoction process is complex, which may result in low utilization of active ingredients (such as polysaccharides, saponins, flavonoids, etc.) and a relatively slow onset of action; moreover, the formulation requires precise diagnosis and is relatively inconvenient to use. Western medicine treatment: Long-term use of qi-tonifying energy supplements (such as amino acid injections) may cause gastrointestinal side effects or increase metabolic burden; iron supplements for blood replenishment are prone to causing adverse reactions such as constipation and nausea, and their absorption rate is affected by various factors. Limitations of single components: Whether it is a single component such as saponins or polysaccharides, or iron, it is difficult to comprehensively regulate the complex pathological mechanisms involving multiple targets and systems related to qi and blood deficiency (such as hematopoietic function, immune regulation, and antioxidation).

[0005] Codonopsis lanceolata, a plant used both as food and medicine, is rich in protein (11%-15%), polysaccharides, saponins, and various trace elements. Existing research largely focuses on the anti-tumor effects of its polysaccharides (e.g., patent CN201810473358.4) or cultivation and processing techniques (e.g., patent CN201310334283.9). However, research on the comprehensive efficacy of its rich oligopeptide components in "tonifying both qi and blood," particularly for the application in treating qi and blood deficiency syndromes, is almost nonexistent. Traditional water extraction methods yield low-yield proteins from Codonopsis lanceolata, with a wide molecular weight distribution and limited bioavailability. Recent studies have shown that oligopeptides (molecular weight <3000 Da) have significant advantages: they can be directly and efficiently absorbed by the intestines, rapidly replenishing various amino acids needed for protein and heme synthesis; they not only enhance energy metabolism (tonifying qi) but also promote the absorption and function of hematopoietic raw materials (tonifying blood) and regulate immune function. Meanwhile, various plant active ingredients (such as blueberry anthocyanins, longan polysaccharides, and jujube polysaccharides) have been proven to have antioxidant, mitochondrial function-improving, and immune-enhancing effects.

[0006] However, existing technologies have significant shortcomings: they lack a systematic compound formulation that utilizes Codonopsis pilosula oligopeptides, a potential active substance for replenishing both qi and blood, as the core, and scientifically combines it with other plant active ingredients to achieve multiple synergistic effects such as "replenishing qi, generating blood, anti-fatigue, and immune regulation." Such a compound formulation has significant clinical demand and development value for efficiently and comprehensively improving symptoms of qi and blood deficiency. Summary of the Invention

[0007] Therefore, it is necessary to provide at least one oligopeptide composition of Codonopsis pilosula with blood-tonifying and qi-tonifying effects, its preparation method, and its uses.

[0008] In a first aspect of this application, a Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects is provided, comprising the following components in parts by weight:

[0009] The ingredients include 2 to 5 parts of Codonopsis pilosula oligopeptide, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptide, and 0.5 to 1 part of compound nutritional fortifier.

[0010] The Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Arg-Lys-Trp-Ser-Trp-Arg, and the Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Gly-Pro-Ala-Lys-Hyp.

[0011] The compound nutritional fortifier contains vitamins, zinc gluconate, and selenomethionine.

[0012] In some embodiments, the Codonopsis pilosula oligopeptides are prepared by a method comprising the following steps:

[0013] Crushing and sieving: Take dried Codonopsis pilosula, crush it, and sieve it through a sieve with a mesh size of 30-50 to obtain Codonopsis pilosula powder;

[0014] Cellulose hydrolysis: After pre-soaking the Codonopsis pilosula powder in distilled water, 0.5 wt%~1 wt% cellulase was added for enzymatic hydrolysis. The cellulase activity was 15,000 U / g~30,000 U / g. The enzyme was inactivated after hydrolysis.

[0015] Complex enzymatic hydrolysis: Enzymatic hydrolysis is performed using a complex protease with a total enzyme activity of 30,000 U / g to 50,000 U / g, wherein the complex protease comprises bromelain, neutral protease and alkaline protease in a mass ratio of (1~3):(3~5):(2~4); Optionally, the conditions for complex enzymatic hydrolysis are pH 7.5~8.5, 50℃~60℃, and hydrolysis for 3 to 5 hours to obtain the enzymatic hydrolysate;

[0016] Separation and drying; the enzymatic hydrolysate is centrifuged to remove undigested Codonopsis pilosula fiber fragments to obtain a supernatant, which is then separated by an ultrafiltration membrane with a molecular weight cutoff of 2500 Da to 3000 Da. The resulting liquid Codonopsis pilosula oligopeptides are then spray-dried to obtain Codonopsis pilosula oligopeptide powder.

[0017] In some embodiments, the cellulose enzymatic hydrolysis step meets one or more of the following conditions:

[0018] (1) The amount of distilled water added is 10 to 15 times the mass of the Codonopsis pilosula powder;

[0019] (2) The pre-soaking conditions are 45℃~60℃ for 1.5 to 3 hours;

[0020] (3) The conditions for enzymatic hydrolysis are pH 5~6, 45℃~60℃, and enzymatic hydrolysis for 1 to 2 hours;

[0021] (4) The enzyme is inactivated by high temperature treatment.

[0022] In some implementations, the high-temperature treatment temperature is 85°C to 95°C.

[0023] In some implementations, the separation and drying steps meet one or more of the following conditions:

[0024] 1) The centrifugation speed is 7,000 rpm to 10,000 rpm, and the centrifugation time is 5 to 15 minutes;

[0025] 2) The conditions for spray drying are an inlet air temperature of 160℃~180℃ and an outlet air temperature of 70℃~80℃.

[0026] In some embodiments, the molecular weight of the Codonopsis pilosula oligopeptide is less than 1000 Da.

[0027] In some embodiments, the Codonopsis pilosula is Codonopsis pilosula from the Changbai Mountain region.

[0028] In some embodiments, the blueberry extract contains at least 20 wt% anthocyanins.

[0029] In some embodiments, the blueberry extract contains at least 25 wt% anthocyanins.

[0030] In some embodiments, the blueberry extract is prepared by a method comprising the following steps:

[0031] Fresh blueberry pulp is mixed with 3 to 8 times its volume of 70% ethanol, ultrasonicated, filtered, and concentrated under reduced pressure to obtain a concentrated liquid without alcohol taste.

[0032] Add 2 to 5 times the volume of 95% ethanol to the concentrate, let it stand, centrifuge to remove the precipitate, and freeze-dry to obtain blueberry extract.

[0033] In some implementations, the ultrasonic treatment conditions are 50°C to 55°C, 250W to 300W, 35 kHz to 40 kHz, and a duration of 25 to 30 minutes.

[0034] In some implementations, the settling conditions are 3°C to 5°C for 8 to 14 hours.

[0035] In some implementations, the centrifugation conditions are 5000 rpm to 7000 rpm for 5 to 15 minutes.

[0036] In some embodiments, the longan pulp extract, the jujube extract, and the wolfberry extract are each prepared independently by a method comprising the following steps:

[0037] Crushing and sieving: Crush longan pulp, jujube or wolfberry and sieve through a sieve with a mesh size of 15-25 to obtain powder;

[0038] Reflux extraction: Add 8 to 12 times the mass of distilled water to the powder and reflux at 85°C to 95°C at least once, for 1.5 to 2.5 hours each time, and combine the filtrates;

[0039] Concentration and drying: The obtained filtrate was concentrated by 10 times its volume under reduced pressure at 55℃~65℃, and then spray-dried to obtain the extract.

[0040] In some embodiments, the spray drying conditions are an inlet air temperature of 150°C to 160°C and an outlet air temperature of 70°C to 80°C.

[0041] In some embodiments, the fish maw oligopeptides are prepared by a method comprising the following steps:

[0042] The rehydrated and softened fish maw was subjected to stepwise hydrolysis with alkaline protease and flavor protease, followed by enzyme inactivation, separation, and concentration.

[0043] In some embodiments, the rehydration softening includes adding 0.05 wt% to 0.2 wt% NaHCO3 solution at a material-to-liquid ratio of 1:(8~12) and soaking at 4°C for 8 to 14 hours.

[0044] In some embodiments, the stepwise hydrolysis includes alkaline protease hydrolysis and flavor protease hydrolysis; wherein:

[0045] The alkaline protease hydrolysis includes: adding 1 wt% to 2 wt% alkaline protease to the rehydrated and softened fish maw, and hydrolyzing at pH 8 to 10 and 50 to 60°C for 2 to 4 hours to obtain alkaline protease hydrolysate; the enzyme activity of the alkaline protease may be, for example, 30,000 U / g to 70,000 U / g.

[0046] The flavor protease hydrolysis comprises: adding 0.8 wt% to 2 wt% flavor protease to the alkaline protease hydrolysate, and hydrolyzing at pH 6 to 6.5 and 45°C to 55°C for 1.5 to 2.5 hours; the enzyme activity of the flavor protease may be, for example, 20,000 U / g to 40,000 U / g.

[0047] In some implementations, enzyme inactivation is achieved through high-temperature treatment, such as maintaining a temperature of 85°C to 95°C for 10 to 20 minutes.

[0048] In some embodiments, the separation includes: centrifuging to obtain a supernatant and filtering the supernatant.

[0049] The centrifugation conditions can be, for example, 7,000 rpm to 9,000 rpm for 15 to 25 minutes.

[0050] In some embodiments, the filtration includes sequentially subjecting the supernatant to membrane filtration to remove undepolymerized collagen fiber fragments and ultrafiltration to collect components with a molecular weight <3 kDa.

[0051] In some embodiments, the concentration includes concentrating the component with a molecular weight <3 kDa by 4 to 5 times using a nanofiltration membrane with a molecular weight cutoff of 400 Da to 600 Da.

[0052] In some embodiments, the weight ratio of vitamins, zinc gluconate, and selenomethionine in the compound nutritional fortifier is 3:2:1.

[0053] In some embodiments, the vitamins include vitamin B1, vitamin B2, and vitamin B6.

[0054] In some embodiments, the weight ratio of vitamin B1, vitamin B2, and vitamin B6 is 1:1:1.

[0055] In some embodiments, the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects is a liquid preparation, and the liquid preparation further contains water as a solvent.

[0056] In a second aspect of this application, a method for preparing a composition of Codonopsis pilosula oligopeptides with blood-tonifying and qi-tonifying effects is provided. The preparation method includes: sieving and mixing 2 to 5 parts of Codonopsis pilosula oligopeptides, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptides, and 0.5 to 1 part of compound nutritional fortifier.

[0057] The Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Arg-Lys-Trp-Ser-Trp-Arg, and the Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Gly-Pro-Ala-Lys-Hyp.

[0058] The compound nutritional fortifier contains vitamins, zinc gluconate, and selenomethionine.

[0059] In some implementations, sieving is performed using a sieve with a mesh size of 60 to 80.

[0060] In some implementations, the mixing method includes mixing using a three-dimensional motion mixer.

[0061] The mixing speed can be, for example, 200 rpm to 300 rpm, and the mixing time can be, for example, 20 minutes to 30 minutes.

[0062] In some embodiments, the Codonopsis pilosula oligopeptide, the blueberry extract, the longan pulp extract, the jujube extract, the fish maw oligopeptide, and the wolfberry extract are each independently as defined in the first aspect.

[0063] In a third aspect of this application, the use of the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in the first aspect is provided, wherein the use includes at least one of the following:

[0064] (1) Use in the preparation of medicines for the prevention and / or treatment of qi and blood deficiency syndrome;

[0065] (2) Use in the preparation of products for tonifying qi and strengthening the spleen;

[0066] (3) Use in the preparation of products for increasing the levels of cytokines in the blood; optionally, the cytokines include one or more of interleukin-3, erythropoietin, granulocyte colony-stimulating factor and macrophage colony-stimulating factor;

[0067] (4) Use in the preparation of a product for increasing the number of one or more of blood cells, hematopoietic factors, white blood cells and platelets in the blood; optionally, the hematopoietic factors include one or more of erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating factor and interleukin-3;

[0068] (5) Use in the preparation of products for enhancing immunity;

[0069] (6) Use in the preparation of products that promote human hematopoietic function.

[0070] In a fourth aspect of this application, a qi-tonifying product is provided, comprising a Codonopsis pilosula oligopeptide composition having the effects of tonifying blood and qi as described in the first aspect.

[0071] The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects in one embodiment of this application can increase the exhaustive swimming time of qi-deficient mice, increase the spleen index, and improve the anti-fatigue ability of qi-deficient mice; it can also increase the number of blood cells in the blood of blood-deficient mice induced by the combined use of acetylphenylhydrazine and cyclophosphamide, increase the secretion of hematopoietic factors to promote hematopoietic function, improve the body's immunity, and improve the symptoms of blood deficiency in mice.

[0072] This Codonopsis pilosula oligopeptide composition, which has the effects of nourishing blood and qi, is derived from traditional Chinese medicine theory. It is safe, effective, and has few side effects, making it suitable for long-term use.

[0073] Furthermore, the preparation method of this Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects is simple, easy to operate, and suitable for large-scale production. Attached Figure Description

[0074] To more clearly illustrate the technical solutions in the embodiments and examples of this application, and to more completely understand this application and its beneficial effects, the drawings used in the description of the embodiments or examples will be briefly introduced below. Obviously, the drawings described below are merely some embodiments of this application. Those skilled in the art can obtain other drawings based on these drawings without creative effort. It should also be noted that the drawings are all drawn in a simplified form and are only used to conveniently and clearly assist in illustrating this application.

[0075] Figure 1 This application demonstrates the effect of one embodiment of the invention on the body weight of mice with qi deficiency.

[0076] Figure 2 This application demonstrates the effect of one embodiment of the invention on the exhaustion swimming time of mice with qi deficiency.

[0077] Figure 3 This application demonstrates the effect of one embodiment of the invention on the spleen index of Qi-deficient mice.

[0078] Figures 4A to 4E The results of the detection of red blood cells, hemoglobin, hematocrit, white blood cells, and platelets in each group of anemic mice in one embodiment of this application are shown.

[0079] Figures 5A to 5D The results of detecting interleukin-3 (IL-3), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor (M-CSF) in the serum of anemic mice in each group by enzyme-linked immunosorbent assay (*P<=0.05, **P<=0.01). DETAILED DESCRIPTION

[0080] To facilitate understanding of this application, a more complete description will be provided below with reference to the accompanying drawings. Preferred embodiments of this application are shown in the drawings. However, this application can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of this application.

[0081] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0082] In this application, unless otherwise specified, "one or more" means any one of the listed items or any combination of the listed items. Similarly, "one or more" and other instances that otherwise indicate "one or more" shall be understood in the same way unless otherwise specified.

[0083] The terms “combinations thereof,” “any combination thereof,” and “any combination thereof” as used in this application include all suitable combinations of any two or more of the listed items.

[0084] In this application, the word "suitable" in "suitable combination", "suitable method", "any suitable method" etc., shall be defined as being able to implement the technical solution of this application, solve the technical problem of this application, and achieve the expected technical effect of this application.

[0085] In this application, terms such as "further," "even more," "particularly," "for example," "like," "example," and "exemplary" are used for descriptive purposes to indicate that different technical solutions preceding and following each other are related in terms of their coverage, but should not be construed as limiting the preceding technical solution or restricting the scope of protection of this application. In this application, unless otherwise specified, A (e.g., B) indicates that B is a non-limiting example of A, and it can be understood that A is not limited to B.

[0086] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it refers to either "with" or "without" a parallel solution. If multiple "options" appear in a technical solution, unless otherwise specified and there are no contradictions or mutual constraints, each "option" is independent. Unless otherwise specified, the descriptions such as "optionally include" and "optionally contain" in this application, taking "optionally include" as an example, mean "may include or not include."

[0087] The terms “containing,” “comprising,” and “including” as used in this application are synonyms and are inclusive or open-ended, not excluding additional, uncited members or features. Members or features include, for example, materials or components, structures, elements, instruments, etc.; non-limiting examples of members or features include actions, conditions under which actions occur, timing, states, etc.

[0088] In this application, the technical features or solutions described in open-ended language include both closed-ended technical features or solutions consisting of the listed contents and open-ended technical features or solutions that include the listed contents.

[0089] In this application, the exemplary descriptions such as "in some implementations (or embodiments)" and "in one implementation (or embodiment)" may cover, but are not limited to, the following meanings: these solutions can be combined with other solutions in a suitable manner to form new technical solutions.

[0090] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only a non-exhaustive enumeration purpose and should be understood not to constitute a closed limitation on quantity.

[0091] In this application, when numerical intervals (i.e., numerical ranges) are involved, unless otherwise specified, the distribution of selectable numerical values ​​within the numerical interval is considered continuous, and includes the two endpoints of the numerical interval (i.e., the minimum and maximum values), as well as every numerical value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that numerical interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints, which is equivalent to directly listing every integer. When multiple numerical ranges are provided to describe features or characteristics, these numerical ranges can be merged. In other words, unless otherwise specified, the numerical ranges disclosed herein should be understood to include any and all subranges included therein. The "numerical value" in the numerical interval can be any quantitative value, such as a number, percentage, ratio, etc. The term "numerical interval" can be broadly included to include numerical interval types such as percentage intervals, ratio intervals, and proportion intervals.

[0092] In this application, where the method flow involves multiple steps, unless otherwise explicitly stated herein, there is no strict order restriction on the execution of these steps; they can be executed in any order other than those described. Moreover, any step may include multiple sub-steps or multiple stages, which are not necessarily completed at the same time, but can be executed at different times, and their execution order is not necessarily sequential, but can be performed alternately or simultaneously with other steps or parts of the sub-steps or stages of other steps.

[0093] One aspect of this application provides a Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects, comprising the following components:

[0094] The ingredients include Codonopsis pilosula oligopeptides, blueberry extract, longan pulp extract, jujube extract, wolfberry extract, whey protein powder, soybean peptide powder, hibiscus powder, fish maw oligopeptides, and compound nutritional fortifiers.

[0095] In some embodiments, the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects comprises the following components in parts by weight:

[0096] The ingredients include 2 to 5 parts of Codonopsis pilosula oligopeptide, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptide, and 0.5 to 1 part of compound nutritional fortifier.

[0097] I do not wish to be limited by any theory, but I believe that in this combination:

[0098] The core component is Codonopsis pilosula oligopeptide, which has the effects of replenishing qi and blood, regulating the body's qi and blood balance, and enhancing physical fitness.

[0099] The blood-nourishing and qi-tonifying components include blueberry extract, which is rich in antioxidants such as anthocyanins, improves mitochondrial function, enhances the body's metabolic capacity, and helps to replenish qi and blood.

[0100] The ingredients that help replenish blood and qi include longan pulp extract, jujube extract, and wolfberry extract, which have the effects of replenishing blood and qi, strengthening the spleen and nourishing the stomach, and can help improve the symptoms of deficiency of both qi and blood.

[0101] The nutritional fortification components include whey protein, soy peptide powder, and fish maw oligopeptides. These ingredients are rich in high-quality protein and amino acids, which can provide the body with abundant nutritional support and promote the production of qi and blood.

[0102] The functional auxiliary components include hibiscus powder and compound nutritional fortifiers. Hibiscus powder has a certain blood-tonifying effect, while compound nutritional fortifiers can further enhance the overall nutritional balance and efficacy of the formula.

[0103] After creative exploration, the inventors discovered that Codonopsis pilosula oligopeptides and blueberry extract have a certain synergistic effect in replenishing blood and qi. They explored the content of each ingredient separately and applied them to a combination, which significantly increased the exhaustive swimming time of mice with qi deficiency, increased the spleen index, and improved the anti-fatigue ability of mice with qi deficiency. It has the effects of replenishing qi and strengthening the spleen, benefiting the lungs and nourishing the heart, and can effectively relieve the symptoms of qi deficiency and improve the quality of life of patients. It also significantly increased the number of blood cells in the blood of mice with anemia induced by the combination of acetylphenylhydrazine and cyclophosphamide, increased the secretion of hematopoietic factors to promote hematopoietic function, and improved the body's immunity.

[0104] Furthermore, while not wishing to be limited by any theoretical framework, it is believed that the efficacy of the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects may decrease when the amount of Codonopsis pilosula oligopeptide is less than 2 parts, and may decrease when the amount is greater than 5 parts. Similarly, the efficacy may decrease when the amount of blueberry extract is less than 2 parts and greater than 4 parts.

[0105] For example, in the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects, the amount of Codonopsis pilosula oligopeptide is 2 parts, 3 parts, 4 parts, or 5 parts, or any value or range between two values; the amount of blueberry extract is 2 parts, 3 parts, or 4 parts, or any value or range between two values; the amount of longan pulp extract is 2 parts, 3 parts, or any value or range between two values; the amount of jujube extract is 2 parts, 3 parts, or any value or range between two values; and the amount of whey protein powder is 2 parts, 3 parts, or any value or range between two values. Range: The dosage of soybean peptide powder is 2 parts, 3 parts, or any value or range between two values; the dosage of wolfberry extract is 2 parts, 3 parts, or any value or range between two values; the dosage of hibiscus powder is 1 part, 2 parts, or any value or range between two values; the dosage of fish maw oligopeptides is 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, or any value or range between two values; the dosage of compound nutritional fortifier is 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, or any value or range between two values.

[0106] In some embodiments, the Codonopsis pilosula oligopeptide comprises a peptide segment with a sequence such as Arg-Lys-Trp-Ser-Trp-Arg.

[0107] In some embodiments, the fish maw oligopeptide comprises a peptide segment with a sequence such as Gly-Pro-Ala-Lys-Hyp.

[0108] In some embodiments, the compound nutritional fortifier comprises vitamins, zinc gluconate, and selenomethionine.

[0109] In some embodiments, the relative amounts of vitamins, zinc gluconate, and selenomethionine in the compound nutritional fortifier are in a weight ratio of 3:2:1.

[0110] For example, the vitamins include vitamin B1, vitamin B2 and vitamin B6; the relative amounts of the three are, for example, in a weight ratio of 1:1:1.

[0111] In some embodiments, the Codonopsis pilosula oligopeptides are prepared by a method comprising the following steps:

[0112] S100. Crushing and sieving: Take dried Codonopsis pilosula, crush it, and sieve it through a sieve with a mesh size of 30-50 to obtain Codonopsis pilosula powder;

[0113] S200. Cellulose hydrolysis: After pre-soaking the Codonopsis pilosula powder in distilled water, add 0.5 wt%~1 wt% cellulase for enzymatic hydrolysis. The cellulase activity is 15,000 U / g~30,000 U / g. The enzyme is inactivated after hydrolysis.

[0114] S300. Complex enzymatic hydrolysis: Enzymatic hydrolysis is performed using a complex protease with a total enzyme activity of 30,000 U / g to 50,000 U / g, wherein the complex protease comprises bromelain, neutral protease, and alkaline protease in a mass ratio of (1~3):(3~5):(2~4); Optionally, the conditions for complex enzymatic hydrolysis are pH 7.5~8.5, 50℃~60℃, and enzymatic hydrolysis for 3 to 5 hours to obtain an enzymatic hydrolysate;

[0115] S400. Separation and drying; the enzymatic hydrolysate is centrifuged to remove undigested Codonopsis pilosula fiber fragments to obtain a supernatant, which is then separated by an ultrafiltration membrane with a molecular weight cutoff of 2500 Da to 3000 Da. The resulting liquid Codonopsis pilosula oligopeptides are then spray-dried to obtain Codonopsis pilosula oligopeptide powder.

[0116] In some implementations, in step S100, the mesh size of the sieve is, for example, 30 mesh, 35 mesh, 40 mesh, 45 mesh, or 50 mesh.

[0117] In some embodiments, in step S200, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, or 1 wt% of cellulase is added for enzymatic hydrolysis.

[0118] In some embodiments, in step S200, the cellulase activity is, for example, 15,000 U / g, 20,000 U / g, 25,000 U / g, 30,000 U / g, or any range or value between two values.

[0119] In some embodiments, in step S200, the amount of distilled water added is 10 to 15 times the mass of the Codonopsis pilosula powder; for example, 10 times, 11 times, 12 times, 13 times, 14 times or 15 times, etc.

[0120] In some embodiments, in step S200, the pre-soaking conditions are 45°C to 60°C for 1.5 to 3 hours. Exemplarily, the temperature can be 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, or 60°C, etc. The pre-soaking duration can be, for example, 1.5 hours, 2 hours, 2.5 hours, or 3 hours. It is understood that the pre-soaking time can be shortened within this range as the temperature increases. For example, when the pre-soaking temperature is 45°C, the pre-soaking time can be 3 hours.

[0121] In some embodiments, in step S200, the pre-soaking condition is 50°C for 2 hours.

[0122] In some embodiments, in step S200, the enzymatic hydrolysis conditions are pH 5-6, 45°C-60°C, and hydrolysis time is 1 to 2 hours. In some embodiments, the enzymatic hydrolysis conditions are pH 5.5, 50°C, and hydrolysis time is 1.5 hours.

[0123] In some embodiments, in step S200, the enzyme is inactivated by high-temperature treatment. For example, the temperature of the high-temperature treatment is 85°C to 95°C, such as 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, or any range or value between two values.

[0124] In some embodiments, in step S300, the total enzyme activity is 30,000 U / g, 35,000 U / g, 40,000 U / g, 45,000 U / g, 50,000 U / g, or any range or value between two values.

[0125] In some embodiments, in step S300, the complex protease includes bromelain, neutral protease and alkaline protease in a mass ratio of 2:4:3.

[0126] In some embodiments, in step S300, the pH of the compound enzymatic hydrolysis can be 7.5, 8, 8.5, or any range or value between two values; the temperature can be 50°C, 55°C, 60°C, or any range or value between two values.

[0127] In some embodiments, in step S400, the centrifugation speed is 7,000 rpm to 10,000 rpm, and the centrifugation time is 5 to 15 minutes; for example, the centrifugation speed can be 7,000 rpm, 8,000 rpm, 9,000 rpm, 10,000 rpm, or any range or value between two values; the centrifugation time can be 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, or any range or value between two values.

[0128] In some embodiments, in step S400, the centrifugation speed is 8,000 rpm and the centrifugation time is 10 minutes.

[0129] In some embodiments, in step S400, the spray drying conditions are an inlet air temperature of 160°C to 180°C and an outlet air temperature of 70°C to 80°C. For example, the inlet air temperature is 180°C and the outlet air temperature is 80°C.

[0130] In some embodiments, the molecular weight of the Codonopsis pilosula oligopeptide is less than 1000 Da.

[0131] In some embodiments, the Codonopsis pilosula is Codonopsis pilosula from the Changbai Mountain region.

[0132] In some embodiments, the Codonopsis pilosula oligopeptides are prepared by the following method: 1 kg of dried Codonopsis pilosula from Changbai Mountain is pulverized and passed through a 40-mesh sieve, then 12 times its weight of distilled water is added, and the mixture is pre-soaked at 50°C for 2 hours. 0.8% cellulase (enzyme activity 20,000 U / g) is added, the pH is adjusted to 5.5, and the mixture is stirred at 50°C for 1.5 hours for enzymatic hydrolysis, followed by enzyme inactivation at 90°C for 10 minutes.

[0133] Further, complex proteolytic hydrolysis: Add complex protease (bromelain:neutral protease:alkaline protease = 2:4:3, total enzyme activity 40,000 U / g), adjust pH to 7.8, and hydrolyze at 55℃ for 4 hours;

[0134] Further, the enzymatic hydrolysate was centrifuged at 8,000 rpm for 10 minutes, and the supernatant was separated by an ultrafiltration membrane with a molecular weight cutoff of 3,000 Da. The permeate was then spray-dried (inlet air temperature 180℃, outlet air temperature 80℃) to obtain Codonopsis pilosula oligopeptide powder.

[0135] Furthermore, its amino acid sequence is Arg-Lys-Trp-Ser-Trp-Arg, and its molecular weight is 917.0 Da.

[0136] Yield: 18.7% (based on raw material dry weight); essential amino acids account for 38.2%, mainly lysine (12.5%) and arginine (9.8%).

[0137] In some embodiments, the anthocyanin content in the blueberry extract is at least 20 wt%, at least 21 wt%, at least 22 wt%, at least 23 wt%, at least 24 wt%, and at least 25 wt%.

[0138] In some embodiments, the blueberry extract contains 28.5% anthocyanins.

[0139] In this application, the method for determining the anthocyanin content in blueberry extract can be a conventional method for determining anthocyanin content in the art, such as UV-Vis detection.

[0140] In some embodiments, the blueberry extract is prepared by a method comprising the following steps:

[0141] S100'. Fresh blueberry pulp is mixed with 3 to 8 times its volume of 70% ethanol, sonicated, filtered, and concentrated under reduced pressure to obtain a concentrate without alcohol odor;

[0142] S200'. Add 2 to 5 times the volume of 95% ethanol to the concentrate, let stand, centrifuge to remove the precipitate, and freeze-dry to obtain blueberry extract.

[0143] In some embodiments, in step S100', the ultrasonic treatment conditions are 50°C to 55°C, 250W to 300W, 35kHz to 40kHz, and a duration of 25 to 30 minutes.

[0144] In some embodiments, in step S100', the ultrasonic treatment conditions are 50°C, 300 W power, 40 kHz frequency, and 30 minutes.

[0145] In some embodiments, during step S200', the settling conditions are 3°C to 5°C for 8 to 14 hours. For example, the settling time is 12 hours at 4°C.

[0146] In some embodiments, in S200', the centrifugation conditions are 5000 rpm to 7000 rpm for 5 to 15 minutes. For example, the centrifugation conditions are 5000 rpm for 15 minutes.

[0147] In some embodiments, the blueberry extract is prepared by adding 1 kg of fresh blueberry pulp to 5 times its volume of 70% ethanol and sonicating at 50°C (300 W power, 40 kHz frequency, 30 minutes); the filtrate is then concentrated under reduced pressure until no alcohol odor remains.

[0148] Further, add 3 times the volume of 95% ethanol to the concentrate, let stand at 4°C for 12 hours, and centrifuge at 5,000 rpm for 15 minutes;

[0149] Blueberry extract was obtained by precipitation and freeze-drying, with an anthocyanin content of 28.5% (detected by UV-Vis method).

[0150] Preparation of compound extract of longan pulp, jujube and wolfberry: Longan pulp, jujube and wolfberry are mixed in a mass ratio of 1:1:1 and crushed through a 20-mesh sieve; 10 times the mass of distilled water is added and the mixture is refluxed at 90℃ twice for 2 hours each time, and the filtrates are combined.

[0151] Further, the filtrate was concentrated under reduced pressure to a relative density of 1.25 (60°C), and then spray-dried (inlet air temperature 160°C, outlet air temperature 70°C) to obtain a compound extract (polysaccharide content ≥45%).

[0152] In some embodiments, the longan pulp extract, the jujube extract, and the wolfberry extract are each prepared independently by a method comprising the following steps:

[0153] S100''. Crushing and sieving: Crush longan pulp, jujube or wolfberry and sieve through a sieve with a mesh size of 15~25 to obtain powder;

[0154] S200''. Reflux extraction: Add 8 to 12 times the mass of distilled water to the powder and reflux at 85℃~95℃ at least once, for 1.5 to 2.5 hours each time, and combine the filtrates;

[0155] S300''. Concentration and drying: The obtained filtrate was concentrated by 10 times its volume under reduced pressure at 55℃~65℃, and then spray-dried to obtain the extract.

[0156] In some implementations, in step S100'', the mesh size of the sieve is 15 mesh, 20 mesh, 25 mesh, or any range or value between two values.

[0157] In some embodiments, in step S200'', 8, 9, 10, 11, or 12 times the mass of distilled water is added to the powder.

[0158] In some implementations, in step S200'', the reflux extraction temperature is, for example, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, or any range or value between two values.

[0159] In some implementations, in step S200'', the reflux extraction time is, for example, 1.5 hours, 2 hours, 2.5 hours, or any range or value between two values.

[0160] In some embodiments, in S300'', the spray drying conditions are an inlet air temperature of 150°C to 160°C and an outlet air temperature of 70°C to 80°C. For example, the spray drying conditions are an inlet air temperature of 160°C and an outlet air temperature of 70°C.

[0161] It should be understood that longan pulp extract, jujube extract, and wolfberry extract can be prepared simultaneously or separately.

[0162] In some embodiments, an extract is prepared by mixing longan pulp, jujube, and wolfberry in a certain mass ratio.

[0163] For example, longan pulp, jujube, and goji berries were mixed in a mass ratio of 1:1:1, pulverized, and passed through a 20-mesh sieve. Ten times the mass of distilled water was added, and the mixture was refluxed at 90°C twice, each time for 2 hours. The filtrates were combined. The filtrate was concentrated under reduced pressure to a relative density of 1.25 (60°C), and then spray-dried (inlet air temperature 160°C, outlet air temperature 70°C) to obtain a compound extract (polysaccharide content ≥45%).

[0164] In some embodiments, the fish maw oligopeptides are prepared by a method comprising the following steps:

[0165] The rehydrated and softened fish maw was subjected to stepwise hydrolysis with alkaline protease and flavor protease, followed by enzyme inactivation, separation, and concentration.

[0166] In some embodiments, the rehydration softening includes adding 0.05 wt% to 0.2 wt% NaHCO3 solution at a material-to-liquid ratio of 1:(8~12) and soaking at 4°C for 8 to 14 hours.

[0167] In some implementations, the material-to-liquid ratio in the rehydration softening process can be 1:8, 1:9, 1:10, 1:11, or 1:12, etc.

[0168] In some embodiments, the concentration of the NaHCO3 solution may be, for example, 0.05 wt%, 0.1 wt%, 0.15 wt%, 0.2 wt%, or any range or value between two values.

[0169] In some embodiments, the rehydration softening includes adding 0.1 wt% NaHCO3 solution at a material-to-liquid ratio of 1:10 and soaking at 4°C for 12 hours.

[0170] In some embodiments, the stepwise hydrolysis includes alkaline protease hydrolysis and flavor protease hydrolysis.

[0171] For example, the alkaline protease hydrolysis includes: adding 1 wt% to 2 wt% alkaline protease to the rehydrated and softened fish maw, and hydrolyzing at pH 8 to 10 and 50°C to 60°C for 2 to 4 hours to obtain alkaline protease hydrolysate; the enzyme activity of the alkaline protease may be, for example, 30,000 U / g to 70,000 U / g.

[0172] In some embodiments, the alkaline protease hydrolysis includes: adding 1.5 wt% alkaline protease to the rehydrated and softened fish maw, and hydrolyzing at pH 8-10 and 55°C for 3 hours to obtain alkaline protease hydrolysate; the enzyme activity of the alkaline protease may be, for example, 50,000 U / g.

[0173] For example, the flavor protease hydrolysis includes: adding 0.8 wt% to 2 wt% flavor protease to the alkaline protease hydrolysate, and hydrolyzing at pH 6 to 6.5 and 45°C to 55°C for 1.5 to 2.5 hours; the enzyme activity of the flavor protease may be, for example, 20,000 U / g to 40,000 U / g.

[0174] In some embodiments, the flavor protease hydrolysis includes: adding 1.5 wt% flavor protease to the alkaline protease hydrolysate and hydrolyzing at pH 6.5 and 50°C for 2 hours; the enzyme activity of the flavor protease may be, for example, 30,000 U / g.

[0175] In some embodiments, enzyme inactivation is achieved through high-temperature treatment, such as maintaining a temperature of 85°C to 95°C for 10 to 20 minutes. For example, enzyme inactivation is achieved by maintaining a temperature of 90°C for 15 minutes.

[0176] In some embodiments, the separation includes: centrifuging to obtain a supernatant and filtering the supernatant.

[0177] The centrifugation conditions can be, for example, 7,000 rpm to 9,000 rpm for 15 to 25 minutes.

[0178] In some implementations, the centrifugation conditions are 8,000 rpm for 20 minutes.

[0179] In some embodiments, the filtration includes sequentially subjecting the supernatant to membrane filtration to remove undepolymerized collagen fiber fragments and ultrafiltration to collect components with a molecular weight <3 kDa.

[0180] In some embodiments, the concentration includes concentrating the component with a molecular weight <3 kDa by 4 to 5 times using a nanofiltration membrane with a molecular weight cutoff of 400 Da to 600 Da. For example, a nanofiltration membrane with a molecular weight cutoff of 500 Da may be used to concentrate the component with a molecular weight <3 kDa by 5 times.

[0181] In some embodiments, the fish maw oligopeptides are prepared by the following method: the dried fish maw is washed three times with deionized water to remove surface salt and impurities; 0.1% NaHCO3 solution is added at a material-to-liquid ratio of 1:10, and the mixture is soaked at 4°C for 12 hours until it is completely rehydrated and softened.

[0182] Furthermore, a two-enzyme stepwise hydrolysis method using "alkaline protease + flavor protease" was adopted: Step 1: Add 1.5% alkaline protease (enzyme activity 50,000 U / g), pH 9.0, hydrolyze at 55℃ for 3 hours; Step 2: Add 1.0% flavor protease (enzyme activity 30,000 U / g), pH 6.5, hydrolyze at 50℃ for 2 hours.

[0183] Further, the enzymatic hydrolysate was rapidly heated to 90°C and maintained for 15 minutes to inactivate residual enzyme activity. The inactivated solution was then centrifuged at 8,000 rpm for 20 minutes; the supernatant was filtered through a 0.45 μm filter membrane to remove undepolymerized collagen fiber fragments. The filtrate clarity was ≤0.1 (OD680 nm). An ultrafiltration membrane with a molecular weight cutoff of 3 kDa was used, operating at a pressure of 0.4 MPa and a temperature of 25°C.

[0184] Collect the permeate (components with a molecular weight <3 kDa), discard the retentate, remove large molecular impurities (such as unhydrolyzed collagen), and enrich oligopeptides. The permeate is then concentrated 5 times using a nanofiltration membrane with a molecular weight cutoff of 500 Da.

[0185] In some embodiments, the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects is a liquid preparation, and the liquid preparation further contains water as a solvent.

[0186] In another aspect of this application, a method for preparing a composition of Codonopsis pilosula oligopeptides with blood-tonifying and qi-tonifying effects is provided. The preparation method includes: sieving and mixing 2 to 5 parts of Codonopsis pilosula oligopeptides, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptides, and 0.5 to 1 part of compound nutritional fortifier.

[0187] The Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Arg-Lys-Trp-Ser-Trp-Arg, and the Codonopsis pilosula oligopeptide contains peptide segments with sequences such as Gly-Pro-Ala-Lys-Hyp.

[0188] The compound nutritional fortifier contains vitamins, zinc gluconate, and selenomethionine.

[0189] In some embodiments, the oligopeptides of Codonopsis pilosula, blueberry extract, longan pulp extract, jujube extract, wolfberry extract, whey protein powder, soybean peptide powder, hibiscus powder, and fish maw oligopeptides are sieved through a sieve with a mesh size of 60 to 80.

[0190] In some embodiments, the mixing method includes mixing using a three-dimensional motion mixer. The mixing speed may be, for example, 200 rpm to 300 rpm, and the mixing time may be, for example, 20 minutes to 30 minutes. Exemplarily, the mixing speed may be, for example, 200 rpm, 250 rpm, 300 rpm, or any range or value between two of these values.

[0191] In some embodiments, the Codonopsis pilosula oligopeptide, the blueberry extract, the longan pulp extract, the jujube extract, the fish maw oligopeptide, and the wolfberry extract are each independently as defined above.

[0192] In another aspect of this application, the use of the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described above is provided, wherein the use includes at least one of the following:

[0193] (1) Use in the preparation of medicines for the prevention and / or treatment of qi and blood deficiency syndrome;

[0194] (2) Use in the preparation of products for tonifying qi and strengthening the spleen;

[0195] (3) Use in the preparation of products for increasing the levels of cytokines in the blood; optionally, the cytokines include one or more of interleukin-3, erythropoietin, granulocyte colony-stimulating factor and macrophage colony-stimulating factor;

[0196] (4) Use in the preparation of a product for increasing the number of one or more of blood cells, hematopoietic factors, white blood cells and platelets in the blood; optionally, the hematopoietic factors include one or more of erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating factor and interleukin-3;

[0197] (5) Use in the preparation of products for enhancing immunity;

[0198] (6) Use in the preparation of products that promote human hematopoietic function.

[0199] In another aspect of this application, a qi-tonifying product is provided, comprising the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described above.

[0200] In some embodiments, the preparation of the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects includes 4 parts Codonopsis pilosula oligopeptide, 3 parts blueberry extract, 2.5 parts each of longan pulp, jujube and wolfberry extract, 2.5 parts whey protein powder, 2.5 parts soybean peptide powder, 1.5 parts hibiscus powder, 0.3 parts fish maw oligopeptide, and 0.8 parts compound nutritional fortifier (vitamin B1:B2:B6=1:1:1, zinc gluconate:selenomethionine=2:1).

[0201] After passing each component through an 80-mesh sieve, it is fed into a three-dimensional motion mixer at a speed of 20 rpm for 30 minutes.

[0202] Dispense into aluminum foil bags (10 g per bag), seal and store away from light.

[0203] Codonopsis pilosula can enhance the phagocytic function of the reticuloendothelial system, improve spleen function, and significantly improve symptoms of immunodeficiency and fatigue related to blood and qi deficiency. Its oligopeptides, through enzymatic hydrolysis, release small molecule active peptides (molecular weight <1000 Da), making them more easily absorbed by the intestines.

[0204] Blueberries, with their high anthocyanin content (≥25%), can reduce mitochondrial damage caused by oxidative stress by scavenging free radicals, thus improving chronic fatigue in patients with qi deficiency. Longan pulp and jujubes can enhance hemoglobin synthesis and improve blood and qi deficiency. Goji berry polysaccharides regulate T lymphocyte activity and boost immunity.

[0205] Fish maw oligopeptides are rich in glycine and proline, which promote connective tissue repair and improve joint weakness and weakened immunity caused by blood and qi deficiency. Whey protein is rich in branched-chain amino acids (BCAAs), and soybean peptides provide small molecule plant peptides (molecular weight <1000 Da). The two work synergistically to promote protein synthesis and alleviate qi deficiency-related physical exhaustion. Roselle contains vitamin C (≥200 mg / 100g), which, along with selenium and zinc in the compound, enhances superoxide dismutase (SOD) activity and reduces lipid peroxidation levels.

[0206] Vitamins B1, B2, and B6 improve energy metabolism disorders in patients with blood and qi deficiency by promoting the activity of glucose and lipid metabolism enzymes.

[0207] The following are some examples.

[0208] The embodiments of this application will be described in detail below with reference to examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. For experimental methods in the following embodiments where conditions are not specified, reference should be made to the guidelines given in this application, or to experimental manuals or conventional conditions in the art, or to the conditions recommended by the manufacturer, or to experimental methods known in the art.

[0209] Example 1

[0210] (1) Preparation of oligopeptides from Codonopsis pilosula:

[0211] Take 1 kg of dried Codonopsis pilosula from Changbai Mountain, crush it through a 40-mesh sieve, add 12 times its weight of distilled water, and pre-soak at 50°C for 2 hours.

[0212] Cellulose hydrolysis: Add 0.8% cellulase (enzyme activity 20,000 U / g), adjust pH to 5.5, stir at 50℃ for 1.5 hours, and inactivate enzyme at 90℃ for 10 minutes; add complex protease (bromelain:neutral protease:alkaline protease = 2:4:3, total enzyme activity 40,000 U / g), adjust pH to 7.8, and hydrolyze at 55℃ for 4 hours; centrifuge the hydrolysate at 10,000 rpm for 10 minutes, separate the supernatant through an ultrafiltration membrane with a molecular weight cutoff of 3000 Da, and spray dry the permeate (inlet air temperature 180℃, outlet air temperature 80℃) to obtain Codonopsis pilosula oligopeptide powder.

[0213] The preparation method of the active peptide also includes determination of the purity and amino acid sequence of the active peptide: the collected small molecule peptides were detected as a single peak by liquid chromatography, and the structure was determined by high performance liquid chromatography-mass spectrometry. The amino acid sequence was Arg-Lys-Trp-Ser-Trp-Arg, the molecular weight was 917.0 Da, and the yield was 18.7% (based on the dry weight of the raw material); the proportion of essential amino acids was 38.2%, mainly lysine (12.5%) and arginine (9.8%).

[0214] (2) Preparation of blueberry extract:

[0215] Ultrasonic-assisted extraction: 1 kg of fresh blueberry pulp was added to 5 times its volume of 70% ethanol and ultrasonically treated at 50°C (300 W, 40 kHz, 30 min). After filtration, the filtrate was concentrated under reduced pressure until no alcohol odor remained. 3 times its volume of 95% ethanol was added to the concentrate, and the mixture was allowed to stand at 4°C for 12 hours, then centrifuged at 5,000 rpm for 15 min. The precipitate was freeze-dried to obtain the blueberry extract, with an anthocyanin content of 28.5% (detected by UV-Vis method).

[0216] (3) Preparation of compound extract of longan pulp, jujube and wolfberry:

[0217] Longan pulp, jujube, and goji berries were mixed in a mass ratio of 1:1:1 and pulverized through a 20-mesh sieve. Ten times the mass of distilled water was added, and the mixture was refluxed at 90℃ twice, each time for 2 hours. The filtrates were combined. The filtrate was concentrated under reduced pressure to a relative density of 1.25 (60℃) and spray-dried (inlet air temperature 160℃, outlet air temperature 70℃) to obtain a compound extract (polysaccharide content ≥45%).

[0218] (4) Preparation of fish maw oligopeptides:

[0219] The dried fish maw oligopeptides were washed three times with deionized water to remove surface salts and impurities. A 0.1% NaHCO3 solution was added at a material-to-liquid ratio of 1:10, and the mixture was soaked at 4℃ for 12 hours until fully rehydrated and softened. The purpose was to create an alkaline environment to break down collagen fiber bundles and improve subsequent enzymatic hydrolysis efficiency. A two-enzyme hydrolysis method using alkaline protease and flavor protease was employed: Step 1: 1.5% alkaline protease (50,000 U / g activity) was added, pH 9.0, and hydrolysis was carried out at 55℃ for 3 hours; Step 2: 1.0% flavor protease (30,000 U / g activity) was added, pH 6.5, and hydrolysis was carried out at 50℃ for 2 hours. Further, the hydrolysate was rapidly heated to 90℃ and maintained for 15 minutes to inactivate residual enzyme activity. After inactivation, the solution was centrifuged at 8,000 rpm for 20 minutes; the supernatant was filtered through a 0.45 μm filter membrane to remove undepolymerized collagen fiber fragments. The clarity of the filtrate (OD680 nm ≤0.1) was determined. An ultrafiltration membrane with a molecular weight cutoff of 3 kDa was used, operating at a pressure of 0.4 MPa and a temperature of 25°C. The permeate (components with molecular weight <3 kDa) was collected, and the retentate was discarded to remove macromolecular impurities (such as unhydrolyzed collagen), enriching the oligopeptides. The permeate was then concentrated 5-fold using a nanofiltration membrane with a molecular weight cutoff of 500 Da; spray-dried at an inlet temperature of 180°C and an outlet temperature of 80°C; 5% maltodextrin was added as a carrier to obtain fish maw oligopeptides. Their amino acid sequence is Gly-Pro-Ala-Lys-Hyp, and their molecular weight is 525 Da.

[0220] A method for preparing a qi-tonifying product containing Codonopsis pilosula oligopeptides, comprising the following components: 4 parts Codonopsis pilosula oligopeptides, 3 parts blueberry extract, 2.5 parts each of longan pulp, jujube, and wolfberry extract, 2.5 parts whey protein powder, 2.5 parts soybean peptide powder, 1.5 parts hibiscus powder, 0.3 parts fish maw oligopeptides, and 0.8 parts compound nutritional fortifier (vitamin B1:B2:B6 = 1:1:1, zinc gluconate:selenomethionine = 2:1). All components are passed through an 80-mesh sieve and then fed into a three-dimensional motion mixer at 200 rpm for 30 minutes. The mixture is then sealed and stored away from light.

[0221] Comparative Example 1: A composition for a Qi-tonifying product is provided, differing from Example 1 only in that, by weight, the active ingredients of this composition are prepared from the following raw materials: 3 parts blueberry extract, 2.5 parts each of longan pulp, jujube, and wolfberry extract, 2.5 parts whey protein powder, 2.5 parts soybean peptide powder, 1.5 parts hibiscus powder, 0.3 parts fish maw oligopeptide, and 0.8 parts compound nutritional fortifier (vitamin B1:B2:B6=1:1:1, zinc gluconate:selenomethionine=2:1). All components are passed through an 80-mesh sieve and then fed into a three-dimensional motion mixer at 200 rpm for 30 minutes, and stored in a sealed, light-protected container.

[0222] Comparative Example 2: A composition for a Qi-tonifying product is provided, differing from Example 1 only in that, by weight, the active ingredients of this composition are prepared from the following raw materials: 4 parts of Codonopsis pilosula oligopeptide, 2.5 parts each of longan pulp, jujube, and wolfberry extracts, 2.5 parts of whey protein powder, 2.5 parts of soybean peptide powder, 1.5 parts of hibiscus powder, 0.3 parts of fish maw oligopeptide, and 0.8 parts of compound nutritional fortifier (vitamin B1:B2:B6=1:1:1, zinc gluconate:selenomethionine=2:1). All components were passed through an 80-mesh sieve and then fed into a three-dimensional motion mixer at 200 rpm for 30 minutes, and stored in a sealed, light-protected container.

[0223] Effect Example

[0224] 1.1 Construction of a Qi-deficient mouse model

[0225] Female ICR mice, weighing 26±2g, were acclimatized for one week prior to the experiment under a room temperature of 22±2℃, relative humidity of 40%~60%, and a 12-hour light-dark cycle. All mice had free access to water and standard feed. Before the experiment, mice underwent acclimatization swimming training for 4 days, 5 minutes / day in 50cm water at 25±1℃. One day before the experiment, mice were forced to swim to exhaustion with a 10% weight on their tails in 50cm room temperature water. Exhaustion was defined as being unable to return to the surface 10 seconds after sinking. The first exhaustion swimming time was recorded, and mice with significantly different exhaustion times were excluded. Mice were fasted for 24 hours. One day before the experiment, mice were weighed, and those with significantly different weights were excluded. Mice meeting the experimental requirements were randomly divided into 6 groups: blank control group, model control group, positive control group, comparative example group 1, comparative example group 2, and example 1 group.

[0226] 1.2 Drug administration to Qi-deficient mice

[0227] The blank control group was fed routinely without any intervention.

[0228] Other groups were fed a restricted diet of 120g / (kg / d). Every morning at 9:00 AM, mice were placed in a 50cm diameter container with several small platforms inside. Water was added to the container, submerging the platforms by 1cm. Mice were allowed to swim or stand on the platforms. Mice exhibited aversion to water and were unable to sleep normally, requiring partial sleep deprivation. Mice were removed and fed again at 9:00 PM. This process was repeated for 9 days. All groups received medication via gavage starting on day 1 of the experiment. Comparative Example 1, Comparative Example 2, and Example 1 groups received the corresponding composition at 9.6g / kg. The positive control group received ginsenosides at 0.1g / kg. The blank group and model group received an equal volume of distilled water. Administration was once daily for 9 consecutive days. The herbal powder of *Codonopsis pilosula* was a brown powder; a certain mass was weighed before use and dissolved in distilled water to the required concentration, prepared fresh for each use. Ginsenosides were a yellow powder; a certain mass was weighed before use and dissolved in distilled water to the required concentration, prepared fresh for each use. The mice were administered the drug via gavage using a 1mL syringe, with a dosage of 0.3mL per mouse.

[0229] 1.3 Weight measurement of Qi-deficient mice

[0230] Six groups of mice were divided and weighed after administration. The mice were administered the drug for nine days, and were weighed at a fixed time each day.

[0231] 1.4 Determination of swimming time in exhausted mice with qi deficiency

[0232] At the start of the experiment and on day 9 of modeling, the mice's exhaustive swimming time was measured. The first and last exhaustive swimming times of the mice were recorded, and the ratio of the first to last exhaustive swimming times was calculated to determine whether the mice were in a state of fatigue.

[0233] 1.5 Determination of spleen index in Qi-deficient mice

[0234] Nine days after administration, the mice were fasted for 12 hours, then anesthetized and euthanized. The spleens were removed and weighed, and the organ ratios were calculated.

[0235] 1.6 Results of the Qi-deficient mouse experiment

[0236] (1) Nine days after exhaustive swimming (i.e., nine days after drug administration), the body weight of mice in the model group was significantly lower than that in the control group (P<0.001). Nine days after drug administration, compared with the model group, the Example 1 group and the positive group showed a trend of improving the decrease in body weight of mice with qi deficiency, but the results were not statistically significant. See the results below. Figure 1 .

[0237] (2) Effect on the swimming time of exhausted mice: Compared with the blank group, the model group mice showed lethargy and drooping eyes, and their swimming time was shortened, but this was not statistically significant. After administration, compared with the model group, the swimming time of mice in Example 1 group and the positive group was significantly prolonged (P<0.001). The results are shown in [link to results]. Figure 2 .

[0238] (3) Effect on spleen index in Qi-deficient mice: After administration, compared with the blank group, the spleen of mice in the model group was significantly atrophied and the spleen index was significantly reduced (P<0.001); compared with the model group, the decreasing trend of spleen index in the Example 1 group and the positive group was slowed down, but there was no statistical significance. See the results below. Figure 3 .

[0239] 1.7 Construction of an anemia mouse model

[0240] Female ICR mice, weighing 26±2g; Compound donkey-hide gelatin oral liquid: purchased from Shandong Dong-E-E-Jiao Co., Ltd.; Acetylphenylhydrazine: purchased from Solarbio; Cyclophosphamide: purchased from MCE; EPO kit, G-CSF kit, IL-3 kit, and M-CSF kit were all purchased from Shanghai Enzyme-Linked Biotechnology Co., Ltd. Mice were randomly divided into 6 groups: blank control group, model control group, positive control group, comparative example 1 group, comparative example 2 group, and Example 1 group. Except for the blank group, the other groups were subcutaneously injected with acetylphenylhydrazine 20 mg / kg on day 2 of the experiment, and again subcutaneously injected with acetylphenylhydrazine 40 mg / kg on day 4. Simultaneously, starting from day 4, 2 hours after the subcutaneous injection of acetylphenylhydrazine, the mice were intraperitoneally injected with cyclophosphamide 40 mg / kg once daily for 4 consecutive days. The blank group received the same volume of physiological saline as the other groups during model establishment.

[0241] 1.8 Drug administration in an anemic mouse model

[0242] All groups were administered medication by gavage starting on day 1 of the experiment. The dosage for each group was 9.6 g / kg of the compositions in Comparative Example 1, Comparative Example 2, and Example 1, respectively. The positive control group received 10 mL / kg of Compound Donkey-hide Gelatin Oral Solution, while the blank and model groups received an equal volume of distilled water. Administration was once daily for 15 consecutive days. Thirty minutes after the last administration, blood was collected from the eyeballs. A portion of the blood sample was placed in an anticoagulant tube for detecting blood cell levels; the remaining blood sample was allowed to stand at room temperature for 4 hours, then centrifuged at 3000 rpm for 10 minutes to separate the serum, which was then stored at -20°C for later use in the enzyme-linked immunosorbent assay (ELISA) for detecting cytokines in the serum.

[0243] 1.9 Blood routine test and cytokine detection in anemic mice

[0244] The blood cell analyzer detects red blood cells, hemoglobin, hematocrit, white blood cells, and platelets. An enzyme-linked immunosorbent assay (ELISA) kit is used to detect interleukin-3 (IL-3), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor (M-CSF) in serum.

[0245] 1.10 Results of the anemia-deficient mouse experiment

[0246] Blood cell counts showed that, compared with the blank control group, the model group mice had decreased levels of red blood cells, hemoglobin, hematocrit, white blood cells, and platelets, indicating that the combined use of acetylphenylhydrazine and cyclophosphamide could lead to a decrease in blood cell levels in mice. Compared with the model group, the comparative examples 1, 2, and Example 1 groups showed increased levels of red blood cells, hemoglobin, hematocrit, white blood cells, and platelets, indicating that the combined composition had a certain ameliorative effect on the decrease in blood cell levels induced by the combined use of acetylphenylhydrazine and cyclophosphamide in mice. (See attached results.) Figures 4A to 4E Furthermore, the drug provided in this application embodiment is significantly more effective than the comparative example.

[0247] The levels of IL-3, EPO, G-CSE, and M-CSF in the serum of mice in each group were detected by enzyme-linked immunosorbent assay (ELISA). The results showed that compared with the blank control group, the levels of IL-3, EPO, G-CSE, and M-CSE in the model group were all decreased. This indicates that the combined use of acetylphenylhydrazine and cyclophosphamide can lead to a decrease in the levels of IL-3, EPO, G-CSE, and M-CSF in mouse serum. Compared with the model group, the levels of IL-3, EPO, G-CSE, and M-CSF in the serum of mice in Comparative Example 1, Comparative Example 2, Example 1, and the positive control group were significantly increased (*P ≤ 0.05, **P ≤ 0.01). This indicates that the composition has an ameliorative effect on the decrease in cytokines such as IL-3, EPO, G-CSE, and M-CSF caused by the combined use of acetylphenylhydrazine and cyclophosphamide. (See attached results.) Figures 5A to 5D Furthermore, the drug provided in this application embodiment is significantly more effective than the comparative example.

[0248] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0249] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims, and the specification and drawings can be used to interpret the content of the claims.

Claims

1. A composition of Codonopsis pilosula oligopeptides with blood-tonifying and qi-tonifying effects, characterized in that, The Codonopsis pilosula oligopeptide composition comprises the following components in parts by weight: The ingredients include 2 to 5 parts of Codonopsis pilosula oligopeptide, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptide, and 0.5 to 1 part of compound nutritional fortifier. The Codonopsis pilosula oligopeptide contains a peptide segment with a sequence as shown in Arg-Lys-Trp-Ser-Trp-Arg, and the Codonopsis pilosula oligopeptide contains a peptide segment with a sequence as shown in Gly-Pro-Ala-Lys-Hyp. The compound nutritional fortifier contains vitamins, zinc gluconate, and selenomethionine.

2. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in claim 1, characterized in that, The Codonopsis pilosula oligopeptide was prepared by a method comprising the following steps: Crushing and sieving: Take dried Codonopsis pilosula, crush it, and sieve it through a sieve with a mesh size of 30-50 to obtain Codonopsis pilosula powder; Cellulose hydrolysis: After pre-soaking the Codonopsis pilosula powder in distilled water, 0.5 wt%~1 wt% cellulase was added for enzymatic hydrolysis. The cellulase activity was 15,000 U / g~30,000 U / g. The enzyme was inactivated after hydrolysis. Complex enzymatic hydrolysis: Enzymatic hydrolysis is performed using a complex protease with a total enzyme activity of 30,000 U / g to 50,000 U / g, wherein the complex protease comprises bromelain, neutral protease and alkaline protease in a mass ratio of (1~3):(3~5):(2~4); Optionally, the conditions for complex enzymatic hydrolysis are pH 7.5~8.5, 50℃~60℃, and hydrolysis for 3 to 5 hours to obtain the enzymatic hydrolysate; Separation and drying; the enzymatic hydrolysate is centrifuged to remove undigested Codonopsis pilosula fiber fragments to obtain a supernatant, which is then separated by an ultrafiltration membrane with a molecular weight cutoff of 2500 Da to 3000 Da. The resulting liquid Codonopsis pilosula oligopeptides are then spray-dried to obtain Codonopsis pilosula oligopeptide powder. Optionally, the cellulose enzymatic hydrolysis step meets one or more of the following conditions: (1) The amount of distilled water added is 10 to 15 times the mass of the Codonopsis pilosula powder; (2) The pre-soaking conditions are 45℃~60℃ for 1.5 to 3 hours; (3) The conditions for enzymatic hydrolysis are pH 5~6, 45℃~60℃, and enzymatic hydrolysis for 1 to 2 hours; (4) The enzyme inactivation method is high-temperature treatment; the temperature of high-temperature treatment can be selected from 85℃ to 95℃; Optionally, the separation and drying steps meet one or more of the following conditions: 1) The centrifugation speed is 7,000 rpm to 10,000 rpm, and the centrifugation time is 5 to 15 minutes; 2) The conditions for spray drying are an inlet air temperature of 160℃~180℃ and an outlet air temperature of 70℃~80℃; Optionally, the molecular weight of the Codonopsis pilosula oligopeptide is less than 1000 Da; Optionally, the Codonopsis pilosula is Codonopsis pilosula from the Changbai Mountain region.

3. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in claim 1, characterized in that, The blueberry extract contains at least 20 wt% anthocyanins, and optionally at least 25 wt%. Optionally, the blueberry extract is prepared by a method comprising the following steps: Fresh blueberry pulp is mixed with 3 to 8 times its volume of 70% ethanol, ultrasonicated, filtered, and concentrated under reduced pressure to obtain a concentrated liquid without alcohol taste. Add 2 to 5 times the volume of 95% ethanol to the concentrate, let it stand, centrifuge to remove the precipitate, and freeze-dry to obtain blueberry extract. in: The conditions for ultrasonic treatment can be selected as 50℃~55℃, 250W~300W, 35 kHz~40 kHz, and a duration of 25 to 30 minutes; The settling conditions can be 3℃~5℃ for 8 to 14 hours; The centrifugation conditions can be selected as 5000 rpm to 7000 rpm for 5 to 15 minutes.

4. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in claim 1, characterized in that, The longan pulp extract, the jujube extract, and the wolfberry extract are each prepared independently by a method comprising the following steps: Crushing and sieving: Crush longan pulp, jujube or wolfberry and sieve through a sieve with a mesh size of 15-25 to obtain powder; Reflux extraction: Add 8 to 12 times the mass of distilled water to the powder and reflux at 85°C to 95°C at least once, for 1.5 to 2.5 hours each time, and combine the filtrates; Concentration and drying: The obtained filtrate was concentrated by 10 times its volume under reduced pressure at 55℃~65℃, and then spray-dried to obtain the extract; Optionally, the spray drying conditions are an inlet air temperature of 150℃~160℃ and an outlet air temperature of 70℃~80℃.

5. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in claim 1, characterized in that, The fish maw oligopeptides were prepared by a method comprising the following steps: The rehydrated and softened fish maw was subjected to stepwise hydrolysis with alkaline protease and flavor protease, followed by enzyme inactivation, separation, and concentration. Optionally, the rehydration softening includes adding 0.05 wt% to 0.2 wt% NaHCO3 solution at a material-to-liquid ratio of 1:(8~12) and soaking at 4°C for 8 to 14 hours; Optionally, the stepwise hydrolysis includes alkaline protease hydrolysis and flavor protease hydrolysis; wherein: The alkaline protease hydrolysis includes: adding 1 wt% to 2 wt% alkaline protease to the rehydrated and softened fish maw, and hydrolyzing at pH 8 to 10 and 50 to 60°C for 2 to 4 hours to obtain alkaline protease hydrolysate; the enzyme activity of the alkaline protease is optionally 30,000 U / g to 70,000 U / g. The flavor protease hydrolysis comprises: adding 0.8 wt% to 2 wt% flavor protease to the alkaline protease hydrolysate, and hydrolyzing at pH 6 to 6.5 and 45°C to 55°C for 1.5 to 2.5 hours; the enzyme activity of the flavor protease is optionally 20,000 U / g to 40,000 U / g; Optionally, the enzyme can be inactivated by high-temperature treatment, such as maintaining the temperature at 85℃~95℃ for 10 to 20 minutes; Optionally, the separation includes: centrifuging to obtain a supernatant, and filtering the supernatant; the centrifugation conditions are optionally 7,000 rpm to 9,000 rpm for 15 to 25 minutes; optionally, the filtration includes sequentially performing membrane filtration on the supernatant to remove undepolymerized collagen fiber fragments and ultrafiltration to collect components with a molecular weight <3 kDa. Optionally, the concentration includes concentrating the component with a molecular weight <3 kDa by 4 to 5 times using a nanofiltration membrane with a molecular weight cutoff of 400 Da to 600 Da.

6. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in any one of claims 1 to 5, characterized in that, The weight ratio of vitamins, zinc gluconate and selenomethionine in the compound nutritional fortifier is 3:2:

1. Optionally, the vitamins include vitamin B1, vitamin B2, and vitamin B6; Further optionally, the weight ratio of the vitamin B1, the vitamin B2 and the vitamin B6 is 1:1:

1.

7. The Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in any one of claims 1 to 5, characterized in that, The Codonopsis pilosula oligopeptide composition is a liquid formulation, and the liquid formulation further contains water as a solvent.

8. A method for preparing a composition of Codonopsis pilosula oligopeptides with blood-tonifying and qi-tonifying effects, characterized in that, The preparation method includes: sieving and mixing 2 to 5 parts of Codonopsis pilosula oligopeptide, 2 to 4 parts of blueberry extract, 2 to 3 parts of longan pulp extract, 2 to 3 parts of jujube extract, 2 to 3 parts of whey protein powder, 2 to 3 parts of soybean peptide powder, 2 to 3 parts of wolfberry extract, 1 to 2 parts of hibiscus powder, 0.2 to 0.5 parts of fish maw oligopeptide, and 0.5 to 1 part of compound nutritional fortifier. The Codonopsis pilosula oligopeptide contains a peptide segment with a sequence as shown in Arg-Lys-Trp-Ser-Trp-Arg, and the Codonopsis pilosula oligopeptide contains a peptide segment with a sequence as shown in Gly-Pro-Ala-Lys-Hyp. The compound nutritional fortifier contains vitamins, zinc gluconate, and selenomethionine; Optionally, the material can be sieved through a sieve with a mesh size of 60 to 80. Optionally, the mixing method includes mixing using a three-dimensional motion mixer; the mixing speed is optionally 200 rpm to 300 rpm, and the mixing time is optionally 20 minutes to 30 minutes; Optionally, the Codonopsis pilosula oligopeptide, the blueberry extract, the longan pulp extract, the jujube extract, the fish maw oligopeptide, and the wolfberry extract are each independently defined as described in claims 1 to 7.

9. The use of the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in any one of claims 1 to 7, characterized in that, The intended use includes at least one of the following: (1) Use in the preparation of medicines for the prevention and / or treatment of qi and blood deficiency syndrome; (2) Use in the preparation of products for tonifying qi and strengthening the spleen; (3) Use in the preparation of products for increasing the levels of cytokines in the blood; optionally, the cytokines include one or more of interleukin-3, erythropoietin, granulocyte colony-stimulating factor and macrophage colony-stimulating factor; (4) Use in the preparation of a product for increasing the number of one or more of blood cells, hematopoietic factors, white blood cells and platelets in the blood; optionally, the hematopoietic factors include one or more of erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating factor and interleukin-3; (5) Use in the preparation of products for enhancing immunity; (6) Use in the preparation of products that promote human hematopoietic function.

10. A product for replenishing blood and qi, characterized in that, It contains the Codonopsis pilosula oligopeptide composition with blood-tonifying and qi-tonifying effects as described in any one of claims 1 to 7.

Images